

## Webcast Alert: Isis Pharmaceuticals, Inc. Announces Its Fourth Quarter Financial Results on the Web;

February 4, 2002

Live and Archived Conference Call Notification

CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- In conjunction with Isis Pharmaceuticals, Inc.'s (Nasdaq: ISIP) Fourth Quarter Financial Results, you are invited to listen to its conference call that will be broadcast live over the Internet on Feb. 7, 2002 at 11:00 a.m. Eastern Time.

What: Isis Pharmaceuticals, Inc. to Discuss 4th Quarter 2001 Financial Results □

When: Feb. 7, 2002 at 11:00 a.m. Eastern Time

Where: <http://www.videonewswire.com/event.asp?id=2920> or  
<http://www.isip.com> □

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Ruth Mealey --- 760-603-2331 --- [rmealey@isisph.com](mailto:rmealey@isisph.com)

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 products in its development pipeline, with two in late-stage development and seven in Phase II human clinical trials. LY900003 (ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of nearly 900 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services and access to an extensive gene function database. Isis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at [www.isip.com](http://www.isip.com).

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from <http://www.microsoft.com/windows/windowsmedia/EN/default.asp> and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to [isproducers@prnewswire.com](mailto:isproducers@prnewswire.com) ).

MAKE YOUR OPINION COUNT - Click Here

<http://tbutton.prnewswire.com/prn/11690X29384193>

SOURCE Isis Pharmaceuticals, Inc.

Web site: <http://www.isip.com>

CONTACT: Ruth Mealey of Isis Pharmaceuticals, Inc., +1-760-603-2331, [rmealey@isisph.com](mailto:rmealey@isisph.com)

Audio: <http://www.videonewswire.com/event.asp?id=2920>